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Over the past 20 years, studies of the biocompatibility profile
of peritoneal dialysis solutions (PDF) have evolved from initial
in vitro studies assessing the impact of solutions on leukocyte
function to evaluations of mesothelial cell behavior. More re-
cent biocompatibility evaluations have involved assessments of
the impact of PDF on membrane integrity and cell function in
peritoneal dialysis (PD) patients. The development of ex vivo
systems for the evaluation of in vivo cell function, and effluent
markers of membrane integrity and inflammation in patients
exposed both acutely and chronically to conventional and new
PDF will be interpreted in the context of our current under-
standing of the biology of the dialyzed peritoneum. The avail-
able data indicate that exposure of the peritoneal environment
to more biocompatible PDF is associated with improvements
in peritoneal cell function, alterations in markers of membrane
integrity, and reduced local inflammation. These data suggest
that more biocompatible PDF will have a positive impact on
host defense, peritoneal homeostasis, and the long-term preser-
vation of peritoneal membrane function in PD patients.
Almost 23 years ago, the first published report in-
dicating that conventional, acidic, glucose-containing,
lactate-buffered peritoneal dialysis solutions (PDF) in-
hibited many of the vital functions of leukocytes created
the “science” of PDF biocompatibility [1]. In the pro-
ceeding decade, these initial seminal observations were
developed and extended, initially to include characteriza-
tion of the responsible components [2–5], and thereafter,
the cellular mechanisms by which these PDF compo-
nents modulated leukocyte and mesothelial cell function
[6–11].
The initial studies were all characterized by a focus on
the now well-described inhibitory effects of PDF com-
ponents (or combinations thereof) on cell function. This
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research identified pH, high lactate concentration, hyper-
osmolality, glucose, and glucose degradation products as
major effectors [3, 6, 7, 12]. Over the past decade, the
focus of in vitro and, more recently, rodent studies has
undergone a transition from one focusing principally on
the effects of PDF on host defense to one that seeks to un-
derstand the causes of degenerative changes in the peri-
toneal membrane (see Williams et al, this supplement)
[13, 14]. These investigations often have concentrated on
glucose as a major activator of profibrogenic processes
in the mesothelium, but also have identified the contri-
bution of hyperosmolality and lactate concentrations in
modulating the processes of cell activation related to the
perpetuation of inflammation [15–20].
The data generated from in vitro biocompatibility
studies have generally substantiated the hypothesis that
conventional PDF, despite providing adequate dialysis,
possess characteristics that might contribute to peritoneal
membrane changes that over time can limit the long-term
successful functioning of the peritoneal membrane. Fur-
thermore, we now understand that infection, its associ-
ated inflammation, and exposure to conventional solu-
tions, can all contribute directly or indirectly to changes
in peritoneal membrane structure and function [14, 21].
This has led in the past few years to the development of
new solutions designed with improved biocompatibility
as their key feature.
THE NEED TO EVALUATE THE IMPACT
OF SOLUTIONS IN VIVO
In principle, it can be argued that conventional in
vitro testing, although providing important mechanistic
insights into solution effects on various cell types, does not
address the central issue of whether new dialysis solutions
will result in improved in vivo performance. Our greater
understanding of the processes that drive degenerative
membrane changes during peritoneal dialysis (PD) re-
quire that we provide in vivo evidence of improved
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peritoneal host defense and reduced inflammation and
data demonstrating preservation of the peritoneal mem-
brane. Ultimately, clinical outcome data are needed to
establish improved efficacy of new solutions in long-term
PD. Although appropriately powered studies will be re-
quired to correctly answer this latter question, the past
few years have seen the development of ex vivo studies
that have provided in vivo indications of improved perfor-
mance of the new solutions. The findings of these studies
and their implications will be discussed in the context of
the current understanding of those factors that contribute
to peritoneal membrane and host defense dysfunction in
PD patients.
UNDERSTANDING THE IMPACT OF
SOLUTIONS ON PERITONEAL HOST DEFENSE
Much of the early data generated in biocompatibility
studies was related to the consensus that preservation
of host defense was a key goal in PD patients. Infection
remains the major reason for treatment failure. It is now
also accepted that frequent or severe episodes of peritoni-
tis and its associated inflammation contribute directly to
membrane dysfunction [21]. Clearly implied in the pub-
lished body of in vitro biocompatibility data is the link
between exposure of cells to unphysiologic solutions, im-
pairment of cell function, and ultimately compromised
host defense.
The peritoneal cavity is normally a closed organ system
that effectively manages infectious insult. Frank peritoni-
tis occurs rarely in normal individuals and usually is asso-
ciated with appendicitis, bowel perforation, or abdominal
surgery. However, once activated, a sophisticated array
of humoral and cellular host defense mechanisms com-
bine to limit and clear infection [22]. In PD patients,
although the effectors and mediators involved in
peritoneal host defense are the same as in normal
individuals, it is well established that host defense is
compromised. This is likely due to the presence of
an indwelling catheter that provides a portal of en-
try to microorganisms (primarily skin commencals such
as Staphylococcal species) and to the large volume of
infused dialysate that both reduces the likelihood of
cell/pathogen interaction and dilutes humoral mediators
(antibodies, complement, and other opsonins) [23–25].
Biocompatibility research has been central in character-
izing the biology of the peritoneal cavity by identifying
that its cellular components (both resident and infiltrating
cells) play a pivotal role in host defense, and that infusion
of unphysiologic solutions plays a key role in modulating
the normal behavior of these components [26–30].
It is now well established that the resident cells of
the peritoneal cavity, the mesothelial cells and resident
leukocytes, orchestrate the peritoneum’s response to in-
fection [29, 30]. Together with infiltrating leukocytes, the
current paradigm of host response to bacterial contam-
ination (derived from both studies in PD patients and
animal models) suggests that while resident leukocytes
initiate the process of inflammation through secretion of
proinflammatory mediators such as interleukin (IL)-1,
tumor necrosis factor (TNF), IL-17, and interferon
(IFN)-c , the mesothelium acts as the central gatekeeper
by directing and amplifying the recruitment of specific
leukocyte phenotypes (initially neutrophils and subse-
quently mononuclear cells) through the controlled secre-
tion of specific chemotactic cytokines [31–39]. Thereafter,
acute inflammation is resolved by the downregulation
of chemokine secretion and the promotion of leukocyte
apoptosis that seems to be under the control of IL-6 and
soluble IL-6 receptor (sIL-6R) signaling [31, 40, 41].
It is well known that the clinical severity of symptoms
during infection is dependent on the genotype and phe-
notype of the infective organism and that inflammation
severity, as assessed by the degree of leukocyte influx, cor-
relates with eventual changes in membrane function [21].
At the cellular level, the temporal nature of the recruit-
ment and subsequent removal of specific leukocyte pop-
ulations is critical in this respect [31]. The maintenance of
activated leukocytes within organs is directly related to
increased tissue damage. These data suggest that modu-
lating both the recruitment phase, the residence time, and
the timely removal of activated leukocytes might have
significant clinical benefit in reducing the inflammatory
load within the peritoneal cavity. The timely and effec-
tive resolution of inflammation is the hallmark of compe-
tent host defense and leads to rapid restoration of organ
homeostasis.
Our knowledge of peripheral and peritoneal leuko-
cytes and mesothelial cells has developed considerably
over the past 20 years. This knowledge, based partly on
measurements in stable PD patients and during peritoni-
tis episodes, has provided a better understanding of the
in vivo role of these cell types in peritoneal inflamma-
tion and the changing levels of peritoneal inflammatory
mediators. In essence, this insight has provided us with
tools with which to measure in vivo both peritoneal host
defense and inflammatory status during PD, and to en-
able comparisons between different treatment modalities
or different dialysis solutions. This understanding under-
pins our interpretation of ex vivo data of peritoneal cell
function and the levels of markers in effluent that can be
used to ascertain the status of host defense, cell function,
membrane longevity, and inflammation in PD patients.
UNDERSTANDING THE IMPACT OF PD
SOLUTIONS ON MEMBRANE LONGEVITY
Several studies have now clearly identified that de-
generative structural changes (both fibrosis and vascular
alterations) and alterations in membrane function occur
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when PD patients are dialyzed with conventional solu-
tions, and that these changes are strongly associated with
therapy duration [13, 42, 43]. In the context of PDF, accu-
mulating evidence from both the Biopsy Registry and
clinical studies suggest that solution exposure is an im-
portant factor contributing to these observed changes
[abstract; Craig KJ, J Am Soc Nephrol 12:425A, 2001]
[21]. While the precise mechanisms behind these associa-
tions are not fully understood, animal studies suggest that
exposure to conventional PDF is associated with overpro-
duction of profibrogenic mediators [transforming growth
factor (TGF)-b1, and vascular endothelial growth factor
(VEGF)] that are strongly implicated in fibrotic diseases
of other organ systems [44–49]. In this context, in vitro
data suggest that dysregulated mesothelial cell activation
by conventional PDF components contributes to a profi-
brogenic (and proinflammatory) phenotype. Such in vitro
observations have provided the rationale and impetus for
ex vivo studies aimed at characterizing not only the in
vivo nature of fibrotic and inflammatory changes within
the peritoneal environment over time, but also the impact
on these changes of treatment with more biocompatible
solutions.
UNDERSTANDING THE IMPLICATION OF
INCREASED PERITONEAL INFLAMMATION
We have previously discussed how the inflammatory
load associated with acute infection appears to contribute
to functional changes in the peritoneal membrane [21].
Similarly, morphologic assessment of the parietal peri-
toneum has correlated fibrotic changes with peritonitis
frequency [abstract; Craig KJ, J Am Soc Nephrol 12:425A,
2001] [Williams et al, this supplement]. It is now becom-
ing clear, however, that in addition to the acute effects
of peritonitis, chronic local inflammation also is a feature
of the peritoneal cavity of PD patients. Studies of inflam-
matory markers such as hyaluronic acid (HA) and IL-6
have demonstrated that their levels in the dialysis effluent
increase with therapy duration [50, 51]. Although the pre-
cise factors responsible for this apparent progressive rise
in local inflammation are unclear, there is some prelimi-
nary evidence that it may be related to dialysis solution
exposure [52]. Of interest in this context are observa-
tions of increased mesothelial cell secretion of monocyte
chemoattractant protein (MCP)-1 following exposure to
dialysis solution components (glucose and lactate), be-
cause MCP-1 plays a central role in the recruitment of
mononuclear cells, which is the hallmark of chronic in-
flammation in diseases such as arthritis and Crohn’s dis-
ease [16, 20, 31]. It should be noted that MCP-1 regulation
in the peritoneal cavity is under the control of IL-6/sIL-
6R signaling [20, 31], suggesting that IL-6 effluent levels
are likely to reflect the inflammatory status of the peri-
toneum.
EX VIVO STUDIES: DEVELOPMENT AND
INTERPRETATION
As discussed previously, although the in vitro charac-
terization of solution biocompatibility profiles has facil-
itated the identification of potentially negative factors,
and to some extent driven new solution design, these
studies have provided little direct information on in vivo
performance. Studies using spent dialysate isolated from
different dwell times with conventional solutions demon-
strated that the inhibitory effects of dialysis solutions on
leukocytes and mesothelial cells persisted throughout the
in vivo dwell period, despite the equilibration of dialysis
fluid that occurs with dwell time [11, 53, 54].
Although several authors have reported studies
characterizing predominantly peritoneal macrophages
(PMØ) isolated from the uninfected peritoneal cavity
[24, 55, 56], the earliest examination of the function of
peritoneal cells isolated from PD patients in the con-
text of dialysis solution exposure were performed in the
early 1980s by the group of Verbrugh et al [57]. After
initial studies of cell function in acute dwell effluents,
this group performed what are now recognized as the
first ex vivo study designs, determining the impact of
solution pH on the ability of PMØ, isolated from 30-
minute dwells, to phagocytose and kill Staphylococcus
epidermidis [58]. These pioneering experiments showed
unequivocally that neutralizing the pH of conventional
PDF resulted in a significant increase in PMØ function,
and their subsequent studies showed that both dwell time
and solution glucose concentrations were key factors in
regulation ex vivo PMØ function [59–61] (Fig. 1).
Taken together, these observations provided a key un-
derstanding of the in vivo impact of dialysis solutions.
These studies reported the first evidence for compro-
mised peritoneal cell function in vivo, showed that the
impact on function was dependent on dwell time (see
later), and provided the first observation that modulating
dialysis solutions (e.g., changing the pH or glucose con-
centration) resulted in a measurable effect on peritoneal
cell function.
EX VIVO STUDIES WITH NEW SOLUTIONS:
IMPACT ON PERITONEAL CELL FUNCTION
Although initial ex vivo studies were performed in
the early 1990s, their usefulness for in vivo biocompat-
ibility testing of new solutions was not fully realized
until the new generation of dialysis solutions buffered
with bicarbonate or mixtures of bicarbonate and lac-
tate became available for clinical use almost a decade
later.
Reevaluation of the influence of effluent dwell time
on ex vivo PMØ function confirmed that early during
the dwell the function of both constitutive and stim-
ulated cells was significantly inhibited (Fig. 1). These
Mackenzie et al: Ex vivo studies of peritoneal dialysis patients S-87
40,000
Control
LPS
TN
Fα
,
 
pg
/1
06
 
PM
Ø
30,000
20,000
10,000
0
30
Intraperitoneal dwell time, minutes
60 90 240
Fig. 1. Peritoneal macrophage (PMØ) function with increasing dwell
time indicates compromised host defense in peritoneal dialysis (PD)
patients. The function of PMØ was assessed by measuring both con-
stitutive and lipopolysaccharide (LPS, 100 ng/mL)-stimulated TNFa
release using enzyme-linked immunosorbent assay (ELISA) in cells
isolated from the peritoneal cavity of patients dialyzed with conven-
tional solutions. Data represent the mean (± SD) TNFa release from
PMØ isolated from three separate donors. ∗P < 0.05 vs. 240 minutes,
Student t test.
initial observations provided the rationale for the first
acute single dwell studies in patients on standard dialysis
regimens that aimed to define the importance of solution
pH, buffer composition (40 mmol/L lactate, 38 mmol/L
bicarbonate, or 25 mmol/L bicarbonate/15 mmol/L lac-
tate), and dialysate glucose concentration in modulating
peritoneal cell function [62]. Earlier in vitro studies had
conclusively shown biocompatibility advantages of phys-
iologic pH solutions [63], and the impact of solution pH
was again clearly delineated in these acute dwell exper-
iments [62]. The in vitro studies, however, failed to dif-
ferentiate between the different buffer compositions in
either neutrophil or mesothelial cell function [64]. In the
acute ex vivo studies, however, cell function was better
maintained with the combination of bicarbonate and lac-
tate, particularly in the presence of high glucose concen-
trations (3.86% glucose) (Fig. 4)[62].
While these data did not provide the only rationale
for the final development of the combined bicarbon-
ate/lactate formulation (Physioneal, Baxter Healthcare
Corporation, McGaw Park, IL, USA) [65, 66], they
were important in indicating that the data generated in
the ex vivo/in vivo study environment did not always mir-
ror those generated by in vitro assays. The interpretation
of these effects are complex but are suggestive of several
advantages of the ex vivo approach (Fig. 2).
Subsequent studies followed a different rationale, and
were performed as part of the phase II clinical trials of
bicarbonate (TB) and bicarbonate/lactate (TBL) dialysis
solutions. These studies utilized the acute dwell proto-
col (30-minute dwell), but were based on repeated as-
sessments of ex vivo PMØ function during a four-week
run-in period when patients used conventional solutions,
and repeated measurements during a treatment period
when they were randomized (for 12 weeks) to continu-
ous dialysis with the control or test solutions. The advan-
tage of this design was the ability to examine the impact
both of the solutions and the period of continuous dial-
ysis [67]. These investigations again provided evidence
for significantly improved PMØ function (measured as
their ability to synthesize TNFa following stimulation) in
the presence of neutral pH, with the greatest increment
in PMØ function in the bicarbonate/lactate-buffered
solution [67].
One of the perceived weaknesses of the ex vivo ap-
proach was the reliance on short-term dwell studies to
emphasize the impact of solution pH in modulating cell
function [54, 57]. To address this issue and to examine if
the improvement in PMØ function was maintained over
long periods of continuous dialysis, subsequent studies
were performed in overnight dwell effluent (fully equi-
librated in terms of pH and electrolyte composition) as
part of a Phase III clinical trial of TBL [66]. Peritoneal
macrophage function was assessed during the run-in and
over the six-month trial period. Consistent with previ-
ous observations, continuous dialysis with TBL improved
PMØ function compared to treatment with conventional
solutions, and this improvement was sustained for the du-
ration of the study [68].
Taken together, these three studies consistently
demonstrated improvements in PMØ function in patients
using more biocompatible solutions. While these data
do not provide direct evidence of improved host de-
fense (as would be indicated by a reduction in peritonitis
rates/incidence, severity, or resolution rate) they suggest a
normalization of the peritoneal environment. These data
also provide a rationale for clinical studies addressing the
key issue of the relationship between dialysis solution
composition and susceptibility to peritoneal infection.
EX VIVO STUDIES WITH NEW SOLUTIONS:
IMPACT ON THE PERITONEAL ENVIRONMENT
Current knowledge suggests that a number of factors
contribute to peritoneal membrane degeneration in PD
patients, including infection, the acute inflammation asso-
ciated with infection, chronic exposure to dialysis solution
components, chronic local inflammation, and the systemic
inflammation associated with uremia. Insights into the
pathophysiology of membrane degeneration have been
partly derived from clinical observation and partly by
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Ex vivo experimental procedure:
1.   Infuse test solution into the patient
2.   Allow to dwell for a defined time
      period (30 minutes to 12 hours)
3.   Drain and isolate PMØ and dialysis effluent
4.   Assay PMØ function
5.   Assay effluent for marker levels
Potential advantages of the ex vivo approach:
•   In vivo human study performed in consenting ESRD patients
•   In vivo changes in pH, osmolality, solute flux occur in the experimental system
•   In vivo biological mediators (peritoneal cytokine network) modulate the
    responses
•   Can be performed in patients using different solutions
    to assess biocompatibility parameters
Fig. 2. Ex vivo approach to measure peri-
toneal cell function and effluent markers of
membrane integrity and inflammation.
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Fig. 3. Schematic representation of the
events that control peritoneal membrane
degeneration in peritoneal dialysis. Arrows
indicate the interactions between inflamma-
tion, host defense, and the importance of
dialysis solution components in modulating
cell behavior.
morphologic assessment of peritoneal biopsies [13, 14,
42, 43, 70, 71]. Over the past few years there has been
increasing acceptance that the measurement of soluble
factors in dialysis effluent can provide valuable informa-
tion about the biologic status of the peritoneal cavity.
This has provided us with the opportunity to widen the
scope of ex vivo evaluation of the impact of new PDF on
peritoneal biology.
Pioneering work in this area defined changes in peri-
toneal inflammatory mediators (leukocytes, cytokines,
chemokines, and their endogenous inhibitors) during
peritonitis [72–77]. These studies were seminal to our un-
derstanding of acute inflammation and underpin our cur-
rent understanding of the control of these events [31, 41].
At the same time, it was realized that evaluation of efflu-
ent markers in stable PD patients might also permit the
description of inflammatory and fibrogenic changes that
occur over time in the peritoneal membrane [51, 78–80].
Initial studies in this area have concentrated on two ma-
jor areas, the impact on mesothelial integrity and mark-
ers of local inflammation within the peritoneal cavity.
Cancer antigen 125 (CA125) is a marker of ovarian
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neoplasia and has long been accepted as a marker of
mesothelial cell mass or turnover. In the peritoneal cav-
ity, CA125 is secreted exclusively by these cells [81, 82].
Although there is debate as to the biologic role and regu-
lation of production of CA125, its levels appear to corre-
late overall with mesothelial cell mass and are thereby an
indicator of improved cell integrity and function [78, 79,
83–88].
Initial studies examined CA125 expression in PD pa-
tients converted from conventional solutions to those
with lactate buffer, neutral pH, and low levels of glu-
cose degradation products (GDPs) [89, 90]. These clini-
cal trials demonstrated clearly that conversion to a more
physiologic solution was associated with a significant
(2- to 3-fold) increase in CA125 levels, findings that were
corroborated in more recent studies with a neutral-pH,
lactate-buffered solution [91]. As part of the Phase III
clinical trail of TBL [66], CA125 levels in overnight ef-
fluent were monitored both in the run-in and the treat-
ment phases of the study. Conversion of patients to TBL
was associated with a significant increase (overall 25%
increase) in CA125 levels. Interpretation of the data on
one level is simple as all studies imply increased mesothe-
lial cell mass in more biocompatible solutions. Given that
these cells play a pivotal role in peritoneal host defense
and membrane homeostasis, this would appear to pro-
vide positive data for the efficacy of these solutions in
vivo. The different magnitude of changes with solutions
with different design philosophy is more difficult to inter-
pret. On the one hand, a 2- to 3-fold increase in CA125
expression would seem advantageous, but it suggests a
similar increase in the number of mesothelial cells that is
difficult to accept because the majority were new patients
in whom biopsy data suggest the mesothelium should be
largely intact (Williams et al, this supplement). Clearly,
more data on the expression, complex regulation, and
function of this large molecular weight, mucilaginous gly-
coprotein are required to definitively resolve these issues
[92, 93].
The interpretation of the data on intraperitoneal mark-
ers of inflammation would seem more definitive. The
process of chronic inflammation is activated within the
peritoneal cavity, as evidenced by time-dependent in-
creases in the levels of inflammatory markers such as
IL-6, HA, and TNFa in dialysis effluent [50, 51]. The reg-
ulation of each of these mediators is well understood,
and in the case of IL-6 and TNFa, their role within both
acute and chronic inflammation is clearly documented
[31, 94, 95].
Ex vivo effluent studies have measured both HA,
TNFa, and IL-6 levels in patients treated with conven-
tional PDF and with TBL [96, 97]. In each case, while the
levels of effluent TNFa remained unaltered (and near the
detection limit), levels of HA and IL-6 were significantly
reduced in patients treated with TBL, following both
three and six months of continuous treatment (Fig. 5)
[96, 97]. The TNFa data indicate that activation of en-
dogenous PMØ function was not increased in a more
physiologic environment. The PMØ are the major TNFa-
producing cells in the peritoneal cavity and play a central
role in host defense [98]. Taken together with the evi-
dence of increased ex vivo PMØ function, the data in-
dicate the increased capacity of these cells to respond
when appropriately activated (e.g., during peritonitis on-
set), but that they are not in a state of permanently in vivo
activation and thereby do not contribute to increased lo-
cal inflammation. Given that PMØ are thought to repre-
sent the first line of host defense, normalization of their
function would be seen as advantageous. These data are
corroborated by observations that PMØ function is aber-
rant in PD patients using conventional solutions, leading
to a more proinflammatory phenotype that develops with
time on therapy [99].
The interpretation of the IL-6 data appears straight-
forward in the light of recent data indicating its primary
role in the control of leukocyte recruitment during in-
flammation [31, 41, 94]. Reduced levels of IL-6 in the
peritoneal cavity of patients using TBL provide evidence
of reduced ongoing inflammation. Although the specific
cause of reduced IL-6 levels has not been evaluated, its
importance in regulating the influx of mononuclear cells
(mononuclear phagocytes and lymphocytes), which char-
acterizes both PD and chronic inflammation, is an area
that certainly requires further study. In this respect, the
association between conventional dialysis solution com-
ponents and the induction of MCP-1 synthesis, the major
chemokine responsible for mononuclear cell recruitment
in the peritoneal cavity [33], and its interrelationship with
IL-6 production are clearly of interest [16, 20, 31].
CONCLUSIONS AND FUTURE PERSPECTIVES
In this review we have attempted to provide a ra-
tionale for the use of ex vivo data to evaluate the
impact of new solutions (such as Physioneal) on pa-
rameters of peritoneal host defense (cell function), mem-
brane longevity, and local inflammation in PD patients.
While these data do not provide definitive evidence of im-
proved patient outcome, they are the first step in defin-
ing the in vivo impact of new and more biocompatible
solutions.
Accumulating evidence suggests that the use of more
biocompatible PDF is associated with significant im-
provements in the function of cells (primarily PMØ)
isolated from the peritoneal cavity. These data are impor-
tant in two respects: they appear to represent evidence
of improved host defense status that is clearly important
in the context of the compromised nature of these pa-
tients; and if considered as a surrogate for all cell types
within the peritoneum, they provide indirect evidence
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Fig. 4. Effect of acute (1-hour) dwell on
in vivo peritoneal macrophage function us-
ing lactate (40 mmol/L lactate, pH 5.2), bi-
carbonate (38 mmol/L bicarbonate), or B/L
(25 mmol/L bicarbonate/15 mmol/L lactate,
pH 7.3). Macrophage function is expressed
as unstimulated (control) and lipopolysaccha-
ride (LPS)-stimulated tumor necrosis factor
(TNF)a production. Patients were exposed to
control on day 1 and then randomized to re-
ceive either B on day 2 and B\L on day 3 or
B\L on day 2 and B on day 3. Data are pre-
sented as mean ± SEM. ∗P < 0.05 vs. control.
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Fig. 5. Effect of continuous treatment with
lactate (40 mmol/L lactate, pH 5.2) or B/L
(25 mmol/L bicarbonate/15 mmol/L lactate,
pH 7.3) on the changes in effluent hyaluronic
acid levels and interleukin (IL)-6 in overnight
timed dwell effluents. Data are presented as
mean ± SEM after the run-in phase (t = 0 all
patients treated with control solutions) and
the treatment phase [at 3 and 6 months (t = 3
and t = 6) in patients randomized to control or
B/L solutions]. Data comparisons were made
with repeated measures analysis of variance
(ANOVA). ∗P < 0.05 vs. 0 time.
that all peritoneal cell types will have improved function.
This latter assumption is supported by the data show-
ing increased CA125 levels (a marker of mesothelial cell
integrity) in the presence of biocompatible solutions. It
is now well recognized that the mesothelium, with its
significant biosynthetic capacity, plays a key role in main-
taining peritoneal homeostasis and is pivotal in orches-
trating peritoneal host defense and leukocyte recruitment
[26, 29, 100]. In long-term PD, there is evidence of alter-
ations in leukocyte phenotype and alteration of mesothe-
lial cell morphology, or even loss of these cells from the
peritoneal membrane [13, 99, 101]. Clearly, evidence of
preservation/normalization of cell function and viability
can be interpreted as a positive aspect of the use of more
biocompatible solutions.
Our understanding of the peritoneum and its responses
has developed rapidly over the past two decades, driven
by the use of PD as a therapy and by the science of
biocompatibility. Central in this has been the realiza-
tion that both acute and chronic inflammation, together
with dialysis solution components, contribute to peri-
toneal membrane fibrogenic degeneration, and in some
patients limit the lifespan of the membrane (Fig. 3).
Ex vivo evidence using more biocompatible solutions
would appear to indicate that many of these degenera-
tive events might be influenced by new solution design.
Measurements in dialysis effluent have provided clear ev-
idence of mesothelial cell preservation and reduced in-
traperitoneal inflammation [90, 96] (Fig. 5).
Many questions in the field of PD solution biocom-
patibility remain to be addressed. It is recognized that
long-term clinical observations will be necessary to sub-
stantiate the in vivo results described above. It is equally
recognized that precise interpretation of ex vivo data
is difficult, primarily due to our ignorance of many of
the cellular and molecular processes that contribute to
the membrane changes that occur in PD patients. Over
the next decade, our understanding of these processes
will inevitably increase, supported by both longitudi-
nal observational studies, collection of clinical data, and
basic science. These endeavors will hopefully provide
both an expanded understanding of the natural history
of the dialyzed peritoneal cavity and a more precise
understanding of which factors are prognostic indica-
tors of the health or the degeneration of the peritoneal
membrane.
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